

Table of Contents

ACKNOWLEDGMENTS	VI
ACRONYMS.....	VII
1. INTRODUCTION.....	11
1.1 <i>Allocative Efficiency in HIV and Health</i>	<i>11</i>
2. OBJECTIVES OF THE ANALYSIS.....	12
3. MEXICO'S HUMAN DEVELOPMENT, HEALTH AND FINANCIAL CONTEXT.....	14
3.1 <i>Human Development, Health and Burden of Disease.....</i>	<i>14</i>
3.2 <i>Health Status</i>	<i>15</i>
3.3 <i>HIV/AIDS Burden of Disease in Mexico.....</i>	<i>15</i>
3.4 <i>Overview of the HIV Epidemic.....</i>	<i>17</i>
3.5 <i>Health and HIV Financing.....</i>	<i>18</i>
3.6 <i>Source of HIV and STI Funding.....</i>	<i>21</i>
3.6 <i>Allocation by Program.....</i>	<i>24</i>
3.7 <i>Allocation by Federative State.....</i>	<i>25</i>
3.8 <i>Cost of Treatment</i>	<i>27</i>
3.9 <i>ART Coverage.....</i>	<i>27</i>
3.10 <i>Cost of ART</i>	<i>28</i>
3.10.1 <i>Cost of First-line Treatment.....</i>	<i>32</i>
3.10.2 <i>Cost of Second-line Treatment.....</i>	<i>33</i>
4. METHODOLOGY	35
4.1 <i>The OPTIMA-HIV Model.....</i>	<i>35</i>
4.2 <i>Data Collection, Populations and Programs.....</i>	<i>35</i>
4.3 <i>Calibration.....</i>	<i>37</i>
4.4 <i>HIV Prevalence.....</i>	<i>37</i>
4.5 <i>Diagnoses, Treatment and Deaths</i>	<i>40</i>
4.6 <i>New infections</i>	<i>41</i>
5. RESULTS	41
5.1 <i>Optimizations</i>	<i>41</i>
5.2 <i>What is the Minimum Number of Deaths and New Infections that Can be Achieved at Current and Scaled up Budgets?.....</i>	<i>42</i>
5.3 <i>What is the Minimum Amount of Funding Required to Halve New Infections and Deaths by 2030 if Funds are Allocated Optimally?.....</i>	<i>44</i>
5.4 <i>Other Simulations: How Much Would it Cost to Achieve 90-90-90?.....</i>	<i>45</i>
5.5 <i>Other Opportunities and Challenges in ART Drug Procurement.....</i>	<i>45</i>
5.6 <i>Viability and Sustainability.....</i>	<i>49</i>
6. CONCLUSIONS	50
7. BIBLIOGRAPHY.....	53